HHS will hold off on enforcement against pharmacies compounding six peptides

A temporary HHS policy lets compounders make six peptides before the FDA has decided, though evidence of their safety and effectiveness is thin.

HHS has released a temporary policy that opens the door for compounding pharmacies to make some peptide products. Under it, the department will use enforcement discretion. It will not act against state-licensed pharmacies, federal facilities, or licensed physicians that compound six specific peptides. Those are the same six an FDA advisory committee previously backed. In July 2026, that panel voted to recommend clearing compounders to make them.

The policy comes before the FDA has finished its own work. The agency is still weighing whether to formally allow compounding pharmacies to make peptides. So this is a stopgap based on non-enforcement, not an approval. Health Secretary Robert F. Kennedy Jr. and the MAHA movement have embraced peptides, and the policy widens access to the experimental wellness therapies many of them favor.

For health abundance, this is friction. Access that outruns evidence doesn't make health cheaper or better. It can move spending toward products whose benefits are unproven and put safety risk on patients. Approval standards exist so that more access means more real benefit. The source notes there is little evidence of peptides' safety or effectiveness.

Watch for the FDA's formal decision on compounding, and for whether the policy's temporary status gets a defined end date. Also watch for any reports of adverse events or pricing. One limit on this brief: only the opening of STAT's article is visible to us because the rest is paywalled. The text we saw doesn't name the six peptides, so the full reporting sits with STAT.

Source: STAT